Pausing for Halftime: A Stratified Analysis of Epidemiological Characteristics and Outcomes in CMV-Seropositive Allogeneic HSCT Recipients with Cscmvi before and after Day 100 | Synapse
March 3, 2026
Pausing for Halftime: A Stratified Analysis of Epidemiological Characteristics and Outcomes in CMV-Seropositive Allogeneic HSCT Recipients with Cscmvi before and after Day 100
Puntos clave
CMV-seropositive allogeneic HSCT recipients after Day 100 show differing outcomes.